Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article Text

Commentary

Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?

https://doi.org/10.1136/gut.2010.236521

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Linked article 221846.
Competing interests None.
Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles

Hepatology
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece …

George V Papatheodoridis Spilios Manolakopoulos Giota Touloumi Georgia Vourli Maria Raptopoulou-Gigi Irini Vafiadis-Zoumbouli Themistoklis Vasiliadis Kostas Mimidis Charalambos Gogos Ioannis Ketikoglou Emanuel K Manesis for the HEPNET. Greece Cohort Study Group
Gut 2011; 60 1109-1116 Published Online First: 26 Jan 2011. doi: 10.1136/gut.2010.221846

Read the full text or download the PDF: